news

FDA accepts Mylan and Biocon’s biosimilar biologics license application

0
SHARES

Posted: 12 January 2017 | | No comments yet

This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers…

The US Food and Drug Administration (FDA) has accepted Mylan and Biocon‘s biologics license application for MYL-1401O, a proposed biosimilar trastuzumab.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

This product is a proposed biosimilar to branded trastuzumab, which is indicated to treat certain HER2-positive breast cancers. The anticipated FDA goal date set under the Biosimilar User Fee Act is September 3, 2017.

Mylan President Rajiv Malik commented: “It marks an important step toward increasing access to this treatment option for patients in the US. We believe that our non-clinical and clinical data submitted with the application will demonstrate similarity of the proposed biosimilar trastuzumab to the reference product.

Dr Arun Chandavarkar, CEO and Joint Managing Director, Biocon, said, “It is a major milestone for the Mylan and Biocon collaboration since it is the first US regulatory submission through our joint global biosimilars program.”

Mylan and Biocon’s proposed biosimilar trastuzumab is also under review by the European Medicines Agency (EMA).

Worldwide, nearly 2 million women are diagnosed with breast cancer each year, making it the second most common cancer in the world. HER2-positive metastatic breast cancer is an aggressive form of breast cancer that tests positive for the human epidermal growth factor receptor 2 (HER2), which promotes cancer cell growth. Approximately 20% to 30% of primary breast cancers are HER2-positive.

Share via
Share via